References
- Le Fanu J. The rise and fall of modern medicine. Little, Brown and Company, London (1999).
- Thomas S, Bommann W, Pellicena P et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938–1942 (2000).
- Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. J. Med. 344, 1031–1037 (2001).
- Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl. J. Med. 344, 1038–1042 (2001).
- Gorre ME, Mohammed M, Ellwood K et aZ Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplication. Science 293, 876–880 (2001).
- Von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to 5T1571: a prospective study. Lancet 359, 487–491 (2002).
- Ohyashiki JH, Ohyashiki K, Aizawa S et al. Replication errors in haematological neoplasias: genomic instability in progression of disease is different among different types of leukemia. Clin. Cancer Res. 2, 1583–1589 (1996).